Fig. 1From: Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trialNumber and proportion of patients in full health (EQ-5D state 11111) at each study visit, by study armBack to article page